One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Abstract

Vedolizumab is able to maintain steroid-free clinical remission in up to one-third of patients with UC and CD at week 54 with a reasonable safety profile. A significant number of patients experienced loss of response during the first year of treatment, particularly in patients with CD.